Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Mallinckrodt
Medtronic
Colorcon
Baxter

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for benoxinate hydrochloride; fluorescein sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01361841 Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma Unknown status Centre de recherche du Centre hospitalier universitaire de Sherbrooke N/A 2009-01-01 Intraocular pressure (IOP) is considered to be the main risk factor for progression of glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has changed considerably during the last decades due to the introduction of prostaglandin analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan). There have been several studies to evaluate their effectiveness. The three seem to be equivalent, according to the only study that has compared the molecules. Latanoprost is employed initially, due to its paucity of side effects when compared to the other two analogues. However, if it is not effective, several studies ahve shown that a result is possible using either travoprost or bimatoprost. No study has been conducted to date systematically comparing the three molecules in cases of resistance to latanoprost. In actuality, the investigators patients will receive treatment identical to current practice with the exception of the group continuing with latanoprost. Several studies confirm the benefit of changing prostaglandin analogues if the first has not signficantly decreased the IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects) The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost and travoprost in their IOP-lowering capacity in patients who do not initially respond to latanoprost.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for benoxinate hydrochloride; fluorescein sodium

Condition Name

Condition Name for benoxinate hydrochloride; fluorescein sodium
Intervention Trials
Primary Glaucoma 1
Ocular Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for benoxinate hydrochloride; fluorescein sodium
Intervention Trials
Ocular Hypertension 1
Glaucoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for benoxinate hydrochloride; fluorescein sodium

Trials by Country

Trials by Country for benoxinate hydrochloride; fluorescein sodium
Location Trials
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for benoxinate hydrochloride; fluorescein sodium

Clinical Trial Phase

Clinical Trial Phase for benoxinate hydrochloride; fluorescein sodium
Clinical Trial Phase Trials
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for benoxinate hydrochloride; fluorescein sodium
Clinical Trial Phase Trials
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for benoxinate hydrochloride; fluorescein sodium

Sponsor Name

Sponsor Name for benoxinate hydrochloride; fluorescein sodium
Sponsor Trials
Centre de recherche du Centre hospitalier universitaire de Sherbrooke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for benoxinate hydrochloride; fluorescein sodium
Sponsor Trials
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
AstraZeneca
Moodys
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.